Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Retatrutide is suited for research examining multi-receptor incretin pharmacology, not as a replacement compound in existing GLP-1 or tirzepatide (dual agonist) study designs
Its inclusion in metabolic-medicine conversation reflects the growing willingness of physicians to consider mechanism-first compounds across classes
Many individuals suffer from symptoms without realising the underlying cause
In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), cholelithiasis was reported in 1.1% of ZEPBOUND-treated patients and 1% of placebo-treated patients, cholecystitis was reported in 0.7% of ZEPBOUND-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of ZEPBOUND-treated patients and no placebo-treated patients
Its local pharmacological characteristics provide a new idea for the treatment of obesity.AOD 9604, as an anti-obesity polypeptide targeting subcutaneous adipose tissue, achieves the effect of local fat reduction by activating lipolysis and inhibiting fat production
